EGFR and non-small cell lung carcinoma: Oxnard et al. reported that the outcomes of osimertinib therapy in NSCLC patients found to harbor the EGFR T790M mutation in a plasma ctDNA test were equivalent to patients classified as positive in a tissue-based assay [33].